Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically…
Ultomiris approved in Japan for the prevention of relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) Ultomiris (ravulizumab) has been approved in Japan as the first and only long-acting C5 complement inhibitor for the prevention of relapses in patients with…
Lilly ESG Report Highlights Progress Towards Sustainability Goals Eli Lilly and Company (NYSE: LLY) today released its latest Environmental, Social and Governance (ESG) report showing progress towards the company’s ambitious sustainability goals, which are critical to maintaining a strong and resilient company. Notable…
ABBOTT UNVEILS LATE-BREAKING DATA SHOWING THE WORLD’S FIRST DUAL-CHAMBER LEADLESS PACEMAKER STUDY MET ALL THREE PRIMARY ENDPOINTS Abbott (NYSE: ABT) today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a large-scale study to assess the…
ABBOTT RECEIVES FDA APPROVAL FOR TACTIFLEX™ ABLATION CATHETER FOR TREATMENT OF ABNORMAL HEART RHYTHM Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s TactiFlex™ Ablation Catheter, Sensor Enabled™, the world’s first ablation catheter…
AMGEN RESPONDS TO FTC ACTION RE: PROPOSED ACQUISITION OF HORIZON THERAPEUTICS Amgen (NASDAQ:AMGN) today issued the following statement in response to the U.S. Federal Trade Commission’s (FTC) complaint seeking to block the company’s proposed acquisition of Horizon Therapeutics plc: “Amgen is disappointed by the FTC’s decision…
ABBOTT RECEIVES FDA APPROVAL FOR ITS SPINAL CORD STIMULATION SYSTEMS TO TREAT CHRONIC BACK PAIN IN PEOPLE WHO HAVE LIMITED SURGICAL OPTIONS Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved its spinal cord…
New Sandoz Board of Directors appointed Sandoz takes the next steps to prepare for the planned listing on the Swiss Stock Exchange (SIX): The Novartis Board of Directors has approved the recommendations of the Sandoz Chairman-designate, Gilbert Ghostine, on the structure…
Positive data from two Phase 3 Dupixent® (dupilumab) trials in prurigo nodularis published in Nature Medicine Positive results from two Phase 3 Dupixent® (dupilumab) trials in adults with uncontrolled prurigo nodularis have been published in Nature Medicine. These first published Phase 3 results in this disease…
FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO) Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for…
Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced a multi-year partnership with Just – Evotec Biologics, the Seattle-based subsidiary of Evotec SE. The agreement…
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead’s…